Previous 10 | Next 10 |
Company Overview and History According to its filings , Cryoport ( CYRX ) “became public by a reverse merger with a ‘shell’ company in May 2005.” From the beginning, the company specialized in developing equipment for transporting biological materials at cryogeni...
BOTHELL, Wash. , Aug. 12, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that representatives o...
BioLife Solutions, Inc. (BLFS) Q2 2019 Earnings Conference Call August 08, 2019 4:30 PM ET Company Participants Roderick de Greef - Chief Financial Officer Mike Rice - President & Chief Executive Officer Conference Call Participants George Zavoico - B. Riley FBR Presen...
BioLife Solutions (NASDAQ: BLFS ): Q2 Non-GAAP EPS of $0.04 beats by $0.02 ; GAAP EPS of $0.03 beats by $0.01 . More news on: BioLife Solutions, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BOTHELL, Wash. , Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational hi...
BOTHELL, Wash. , Aug. 8, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a share exchange agreement to effect the ac...
BOTHELL, Wash. , July 31, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's ...
BOTHELL, Wash. , July 30, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies , a leading developer of ad...
BOTHELL, Wash. , July 23, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies , a leading developer of advanced cold...
Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...
News, Short Squeeze, Breakout and More Instantly...
BioLife Solutions Inc. Company Name:
BLFS Stock Symbol:
NASDAQ Market:
BioLife Solutions Inc. Website:
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024 PR Newswire BOTHELL, Wash. , July 25, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction...
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouv...
BioLife Solutions Reports First Quarter 2024 Financial Results PR Newswire Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands ...